0001209191-23-034887.txt : 20230606
0001209191-23-034887.hdr.sgml : 20230606
20230606193620
ACCESSION NUMBER: 0001209191-23-034887
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230602
FILED AS OF DATE: 20230606
DATE AS OF CHANGE: 20230606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gengos Andrew
CENTRAL INDEX KEY: 0001563623
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39503
FILM NUMBER: 23997412
MAIL ADDRESS:
STREET 1: 21900 BURBANK BOULEVARD
STREET 2: 3RD FLOOR
CITY: WOODLAND HILLS
STATE: CA
ZIP: 91367
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athira Pharma, Inc.
CENTRAL INDEX KEY: 0001620463
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 453368487
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104
CITY: BOTHELL
STATE: WA
ZIP: 98011
BUSINESS PHONE: (425) 620-8501
MAIL ADDRESS:
STREET 1: 18706 NORTH CREEK PARKWAY, SUITE 104
CITY: BOTHELL
STATE: WA
ZIP: 98011
FORMER COMPANY:
FORMER CONFORMED NAME: M3 Biotechnology, Inc.
DATE OF NAME CHANGE: 20140924
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-02
0
0001620463
Athira Pharma, Inc.
ATHA
0001563623
Gengos Andrew
C/O ATHIRA PHARMA, INC.
18706 NORTH CREEK PARKWAY, SUITE 104
BOTHELL
WA
98011
0
1
0
0
See Below
0
Common Stock
2023-06-02
4
P
0
10012
2.75
A
10012
D
Common Stock
2023-06-02
4
P
0
6582
2.8598
A
16594
D
Common Stock
2023-06-02
4
P
0
3418
2.945
A
20012
D
Common Stock
2023-06-05
4
P
0
15000
3.00
A
35012
D
Common Stock
2023-06-05
4
P
0
10000
2.9997
A
45012
D
Common Stock
2023-06-05
4
P
0
10000
2.9999
A
55012
D
Common Stock
2023-06-05
4
P
0
10000
3.0154
A
65012
D
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.855 to $2.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.9999 to $3.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.995 to $3.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $2.995 to $3.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Chief Financial Officer and Chief Business Officer
/s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
2023-06-06